Name | Ergoloid Mesylates |
Synonyms | cck179 circanol ergoloid mesylate Ergoloid Mesylates co-dergocrinemesylate dihydroergotoxinmesylate dihydroergotoxinemesilate Dihydroergotoxine Mesilate dihydroergotoxinemethanesulfonate dihydroergotoxinemethanesulphonate dihydroergotoxine monomethanesulphonate dihydroergotoxinemonomethanesulfonate(salt) 12'-hydroxy-5'-(2-methylbutan-2-yl)-3',6',18-trioxo-2'-(propan-2-yl)-9,10-dihydroergotaman |
CAS | 8067-24-1 |
EINECS | 249-539-5 |
InChI | InChI=1/C33H45N5O5/c1-7-31(4,5)27-29(40)37-13-9-12-25(37)33(42)38(27)30(41)32(43-33,18(2)3)35-28(39)20-14-22-21-10-8-11-23-26(21)19(16-34-23)15-24(22)36(6)17-20/h8,10-11,16,18,20,22,24-25,27,34,42H,7,9,12-15,17H2,1-6H3,(H,35,39) |
Molecular Formula | C20H29N3O5S |
Molar Mass | 423.53 |
Density | 1.34g/cm3 |
Boling Point | 846.8°C at 760 mmHg |
Flash Point | 465.9°C |
Vapor Presure | 1.77E-30mmHg at 25°C |
Appearance | neat |
Storage Condition | Store at RT |
Refractive Index | 1.66 |
Use | Dihydroergotoxine mesylate is a series of alkaloid salt mixtures. |
Hazard Symbols | T - Toxic |
Risk Codes | 60 - May impair fertility |
Safety Description | S53 - Avoid exposure - obtain special instructions before use. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | 1544 |
RTECS | KE8800000 |
HS Code | 3003490000 |
Hazard Class | 6.1(b) |
Packing Group | III |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 0.432 ml | 2.16 ml | 4.32 ml |
5 mM | 0.086 ml | 0.432 ml | 0.864 ml |
10 mM | 0.043 ml | 0.216 ml | 0.432 ml |
5 mM | 0.009 ml | 0.043 ml | 0.086 ml |
contraindications | allergic to this product, severe liver, renal insufficiency, acute and chronic psychosis, hypotension, severe arteriosclerosis, organic heart damage, severe bradycardia and pregnant women. |
Application | cerebrovascular insufficiency, senile brain function change or various symptoms of sequelae of cerebrovascular accident, especially accompanied by Vertigo, tinnitus and other cochlear and vestibular dysfunction and visual impairment. dihydroergotoxine mesylate sustained-release tablets are composed of hydrogenated ergotin, hydrogenated ergocomin, α-hydrogenated ergocryptin and β-hydrogenated ergocryptin in accordance with the ratio of 3:3:2: mixed in a ratio of 1. It has an agonistic effect on the DA1 and DA2 receptors in DA, which can agonize the DA receptor on the nodular-funnel pathway, which can theoretically reduce prolactin levels, this also explains the decline in prolactin levels after 8 weeks in the treatment group. Ergotoxine mesylate sustained-release tablets can inhibit ATPase and adenylate cyclase activity, reduce the decomposition of ATP, improve the ability of brain cells, increase the energy of neurons, and improve the potential activity. It also affects the DA receptor and the 5-HT receptor. In addition, it can block alpha receptors, dilate cerebral blood vessels and improve cerebral blood flow. The effects of noradrenergic system, cholinergic system, serotonergic system, DA system and GABAergic system on P300 potential were observed. In this study, the treatment group 8 weeks after the Cz point amplitude was statistically significant increased compared with the baseline, which may be related to the effect of dihydroergotoxine mesylate on a variety of neurotransmitters in the brain, thereby improving cognitive function, the latency and amplitude of P300 were affected. |
note | (1) slightly slow rhythm should be used with caution. (2) This product may inhibit milk secretion, not recommended for lactating women. (3) the combination of this product and anticoagulant drugs may reduce the activity of this product. (2) with the combination of antihypertensive drugs, may reduce the activity of the product and increase the hypotensive reaction, both should avoid the combination. (3) combined with thiazide drugs, can aggravate hypotension, both should avoid the combination. (4) when combined with dopamine drugs, it can induce peripheral vasospasm, especially lead to distal limb vasoconstriction, so it should not be combined with this kind of drugs. |
biological activity | Dihydroergotoxine mesylate is a series of alkaloid salt mixtures with high binding activity to GABAA receptors. |